Is MOTS-c legal? FDA status, the July 2026 vote and what the evidence shows

The short version. MOTS-c is not FDA approved and is not on the 503A Bulks List. An advisory committee voted for listing it on 23 July 2026, a recommendation the FDA is not bound by. FDA staff recommended against, citing no study in humans by any route, no toxicity studies and quality concerns.

What is MOTS-c?

MOTS-c is a 16 amino acid peptide encoded inside mitochondrial DNA, in a short stretch of the 12S rRNA gene; the name stands for mitochondrial open reading frame of the 12S rRNA type-c. The FDA briefing document prepared for the July 2026 Pharmacy Compounding Advisory Committee says the peptide was first described by Lee and colleagues in 2015, occurs naturally in muscle, heart and brain, and circulates in the blood of humans and rodents. The MOTS-c sold online is a synthetic version made by standard solid-phase peptide synthesis. Because the body makes its own MOTS-c, sellers present the injectable as a natural top-up, but the FDA found no study showing what happens when a person injects it.

MOTS-c also has the naming problem the FDA found across the July review. The single nomination, from Wells Pharmacy Network, did not make clear whether it meant MOTS-c free base or MOTS-c acetate, which are different active ingredients: its certificate of analysis named the acetate while its registry numbers matched the free base. The agency evaluated both on its own initiative after the nomination was withdrawn. Online, the FDA found clinics and sellers marketing MOTS-c for mitochondrial energy, weight loss, insulin resistance, physical performance, DNA repair and slower cellular ageing, and one wellness clinic offering it in an IV cocktail. Those claims come from sellers, not from an approval or a completed trial.

In plain EnglishMOTS-c is a small peptide your own mitochondria make. A lab-made version is sold as an injection for weight and energy. In the US it is not an approved drug, and the FDA found no published study of giving it to people.

Is MOTS-c legal in 2026?

MOTS-c's legal position rests on three dated facts. First, the FDA briefing states that neither MOTS-c free base nor MOTS-c acetate is a component of an FDA approved drug, and neither has a USP or National Formulary monograph. Second, MOTS-c is not on the 503A Bulks List, and the FDA page on 503A bulk substances, current as of 14 May 2026, does not name it. Third, the FDA safety-risk page, current as of 22 April 2026, lists MOTS-c among substances whose nominations were withdrawn, noting that the FDA has not identified any human exposure data by any route and lacks information on whether it would cause harm in people. Law firm McDermott Will & Schulte reported that HHS confirmed the move out of Category 2 on 15 April 2026, and stressed that leaving Category 2 is not Category 1.

The committee vote is the fact most often misreported. On 23 July 2026 the committee voted separately on MOTS-c free base and MOTS-c acetate, and McDermott Will & Schulte and the FDA Law Blog reported the result as 7 in favour, 5 against and 2 abstentions. The FDA Law Blog called it the closest vote of the day, and its two abstentions were the most of any peptide the committee backed that week. McDermott lists the uses under review as obesity and osteoporosis. The FDA Law Blog reported that opponents, including Public Citizen and the Partnership for Safe Medicines, argued that listing would amount to a large, uncontrolled human trial without adverse event reporting. As of 13 October 2026 the FDA meeting page carried no minutes, and no rule had been proposed. A page that calls MOTS-c "now legal to compound" is describing a rule that does not exist yet.

In plain EnglishA committee said yes by two votes. The FDA has not acted on it. Until it does, MOTS-c is in the same legal position it was in before the vote.

MOTS-c is sold for weight loss and longevity. The FDA found no study in which it was given to a human, by any route, and no toxicity study in animals.

The Ozemback peptide legal status tracker carries MOTS-c in the "recommended, not law" group alongside BPC-157, TB-500, KPV, Epitalon and Semax, with the date of each fact. MOTS-c closed the first day of the July 2026 meeting, and emideltide was the only peptide voted down across the two days. The tracker will change the MOTS-c row on the day the FDA proposes or finalises a rule, because that is the event that would alter its legal status. For how the committee overrode its own staff across the meeting, see our analysis of the vote. To test what you know, try the approved, recommended or neither quiz.

What does the evidence for MOTS-c show?

The FDA's conclusion: a lack of evidence to evaluate effectiveness for any nominated use, no clinical studies in humans, and no in vivo pharmacokinetic data.

The nomination proposed MOTS-c injections for insulin resistance, obesity, osteoporosis, vascular calcification, muscle and fat metabolism, and longevity. The FDA did not evaluate any of those uses, because the nomination lacked the information needed and because the agency could find no clinical study of any of them. The nominator submitted 10 pharmacology articles and cited 12 references in support of effectiveness, none of them clinical. What the record does contain is animal work: mice on a high-fat diet that gained less weight and stayed more sensitive to insulin, ovariectomised mice that gained less fat, rats with less vascular calcification, and bone cells in a dish that behaved more like bone-building cells. All of it is in rodents or cultured cells.

The most quoted MOTS-c result is a lifespan figure. In Reynolds and colleagues in 2021, male mice started on intermittent MOTS-c late in life lived a median of 970 days against 912 for untreated mice, and a maximum of 1,120 days against 1,047, as summarised in the FDA briefing. The FDA's caution is specific: the studies are restricted to rodents, none assessed dose-response, and the molecular target through which MOTS-c acts remains unknown, which makes it difficult to predict which organs it affects. The one pharmacokinetic-related study the FDA found incubated MOTS-c in human blood in a test tube and reported that it broke down rapidly into shorter fragments, which raises the question of whether an injection can reach active levels at all.

In plain EnglishMice and cells responded in interesting ways. No person has been studied. The FDA concluded there is nothing yet to show MOTS-c works for weight, blood sugar, bones or ageing in humans.

What has been reported on safety

The FDA's safety conclusion is that potential risks of MOTS-c in humans are unknown. Its FAERS searches, through 9 March 2025, returned no reports, but compounders generally do not report adverse events, so an empty database proves little. The agency found no acute, repeat-dose, genetic, reproductive or carcinogenicity toxicity studies of either form. It flagged immunogenicity as its main concern: a 16 amino acid peptide injected under the skin can aggregate, and aggregates and synthesis impurities can trigger immune responses, which in the FDA's words can range from no visible effect to life-threatening reactions, or antibodies that neutralise the body's own MOTS-c. No certificate of analysis it reviewed showed impurity, endotoxin or bioburden testing.

What is the MOTS-c dosage?

There is no FDA approved dose of MOTS-c, because there is no FDA approved product.

Every MOTS-c dose figure you will find in the US comes from somewhere other than a US label. The nomination proposed lyophilised vials for injection without saying how they would be reconstituted, and the animal studies dosed by body weight in mice and rats, which does not translate into a human dose. The FDA found no pharmacokinetic study in people or living animals, so the record it reviewed says nothing on how the body absorbs or clears injected MOTS-c, and outsourcing facilities reported compounding no MOTS-c product between January 2017 and December 2025. We report this because it is the record, and we do not publish a recommended dose, cycle or protocol for MOTS-c or any other compound.

What is still unknown about MOTS-c?

• Whether it does anything in people. No clinical study of MOTS-c exists in the record the FDA reviewed.
• Whether an injection survives. In human blood in a test tube it broke down quickly; no study has measured levels after injection.
• What it acts on. The molecular target is unknown, so the organs it affects cannot be predicted.
• Whether it is toxic. No animal toxicity study of any kind was found.
• What is in a given product. Sellers rarely say which form they sell, and no certificate the FDA reviewed showed endotoxin or impurity testing.
• Whether the FDA will follow the committee. The agency is not bound by the July 2026 vote, and no rule had been proposed as of 13 October 2026.

How should you read other pages about MOTS-c?

Check whether the page treats mouse results as if they were human results; every weight, insulin and lifespan figure in the record comes from rodents. Check whether it uses the fact that the body makes MOTS-c as proof that an injection is safe; the FDA found no data on injecting it. Check whether it reports the July 2026 vote as a recommendation or as a change in the law; only the first is accurate. Check who pays the author: nearly every site ranking for MOTS-c benefits or dosage sells it, sells a consultation or links to a seller. This page carries a date at the top, 13 October 2026, so you can tell when it stops being current. Related files: BPC-157 and TB-500, voted on the same day.

The questions people actually type

Sources